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OBJECTIVE: The purpose of this study was to examine
concomitant medications use and associated costs in
hepatitis-C (HCV) patients before and after HCV treat-
ment in a large managed care population. METHODS:
Continuously beneﬁt-eligible patients were identiﬁed
from a managed care database of integrated medical 
and pharmacy claims (~10 million lives). A total of 1812
patients with a new HCV diagnosis between June 1, 2001
and December 31, 2001, who had no HCV-related
medical and prescription claims in a 12-month pre-
diagnosis period and had up to 12 months of medical
follow-up were included in the study. Concomitant med-
ications included all drugs prescribed for treatment of
anemia, neutropenia, depression, and sleeping disorders
that were dispensed between the ﬁrst and last HCV pre-
scription ﬁll date. RESULTS: The study subject median
age was 46 years and 62% were male. The HCV treat-
ment rate was 17% (314 treated vs 1498 untreated) with
a mean of 2.6 months of elapsed time between HCV diag-
nosis and initial HCV prescription claim. Concomitant
medication use was lower in the pre-diagnosis period than
in the follow-up period for anemia agents (3% vs. 9%, p
= 0.004), neutropenia agents (1% vs. 3%, p = 0.05), anti-
depressants (18% vs. 31%, p < 0.0001), non-barbiturate
sedatives (8% vs. 21%, p < 0.0001), and overall con-
comitant use (23% vs. 45%, p < 0.0001). Consequently,
mean cost associated with concomitant drug use was
higher during the HCV therapy as compared to the pre-
diagnosis period ($761 vs. $457, p < 0.0001). CON-
CLUSIONS: In this sample of HCV treated patients, 45%
were prescribed concomitant medications for treatment
of HCV-related conditions during the follow-up period
compared to only 23% in the pre-diagnosis period. This
pattern suggests a cost consequence on concomitant drug
use during HCV therapy. More research is needed to
better understand the association between these con-
comitant agents and cost implications of HCV treatment
in this patient population.
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OBJECTIVES: Abacavir causes hypersensitivity reactions
(HSRs) in about 4% of HIV patients. HSRs can be
serious, result in hospitalisations and incur signiﬁcant
Health care expense. Recent evidence suggests that the
presence of HLA-B57 increases the likelihood of occur-
rence of HSRs. The aim of this analysis is to model the
cost-effectiveness of genotyping, which costs £30 per
patient, as a therapeutic strategy to avoid abacavir—
induced hypersensitivity reactions. METHODS: As HSRs
occur within the ﬁrst few weeks of therapy, a 6-month
time horizon was chosen for the analysis that adopted a
UK National Health Service perspective. Data relating to
time of onset and prevalence of HSRs were obtained from
published sources. An analysis of test characteristics (sen-
sitivity and speciﬁcity) was performed by pooling data
from two previously published studies with data of our
own. The use of Health care resources, and associated
costs of treating HSRs were collected from the records of
16 patients. The cost and selection of substitutes for aba-
cavir (alternative HAART regimens), in the case of posi-
tive testing or occurrence of HSR, were considered in the
analysis but assumed to be equally efﬁcacious. A proba-
bilistic decision analytic model (comparing testing versus
no testing) was formulated and Monte Carlo simulations
performed. RESULTS: When abacavir is used as salvage
therapy, genotyping is cost saving. When used in treat-
ment naïve patients or for regimen simpliﬁcation, the
ICER of genotyping versus conventional “blind” therapy
ranged from being cost saving to £4000 per HSR avoided,
depending on the cost of alternative regimen: the more
expensive the alternative, the less cost effective the test 
is. CONCLUSIONS: Pharmacogenetic testing to prevent
abacavir—induced HSRs appears to be a cost effective use
of Health care resources. A recommendation of routine
adoption of testing for patients eligible for abacavir
therapy may be appropriate.
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OBJECTIVE: To estimate the cost-effectiveness of pegin-
terferon alfa-2a 180mcg/week and ribavirin 1000mg/d
(PegINF + R) relative to interferon alfa-2b 3mln units
thrice weekly and ribavirin 1000mg/d (INF + R) in
chronic hepatitis C patients without preexisting cirrhosis.
METHODS: A Markov model was developed to project
lifelong clinical and economic outcomes in 45-year-old
patients based on published in literature transition prob-
abilities and utility values and Polish data on health care
resource utilisation and unit cost. The duration of treat-
ment was 48 weeks and 24 weeks respectively in patients
with HCVgenotype-1 (group I) and non-1 (group II). Pre-
dictability test was performed after 12 weeks and 24
weeks in those receiving PegINF + R and INF + R respec-
tively. Effectiveness was expressed in LY and QALY. Only
direct medical costs were analysed from Health care
payer’s perspective. The cost-effectiveness threshold was
calculated on the basis of 1-year haemodialysis treatment
cost (60,000 PLN, €1 = 4 PLN; in 2003). Sensitivity
analyses were performed to test the robustness of the
model. RESULTS: PegINF + R relative to INF + R
increased life expectancy by 0.78 LY or 0.46 QALY in
group I and 1.17 LY or 0.78 QALY in group II. The
cost/patient treated with PegINF + R or INF + R was
